Pricing of Brilacidin could prove quite a problem
Post# of 72440
(Total Views: 577)
Posted On: 07/31/2020 12:27:35 PM
Pricing of Brilacidin could prove quite a problem IMO.
The world wants the CV19 treatment (and thus a treatment for what should be quite a host of other viruses)to be priced as low as possible so everybody could afford it worldwide. So now you have a very low cost (comparatively speaking) for B-IV.
Now go to the B-ABSSSI indication for infections and the need to be able to kill superbugs. I have read where leading antibiotic experts say that a price of $10,000 per treatment would be a steal (compared to some other disease and cancer drugs that go up to $1MM / treatment)if it could save patients where nothing now can.
How can you charge $10,000 for the IV for ABSSSI to get the payback necessary for startups to develop such new antibiotics when you are selling the exact same IV for CV and virus treatment patients at a rock bottom price of say $800 / treatment?
Take the same path for COPD, kidney problems, bowel problems, etc, etc. That is why I believe the entire B platform must be handled by a single BP. They would make enough in bulk and have enough patients to generate massive revenues while being able to price B at a reasonable level.
The world wants the CV19 treatment (and thus a treatment for what should be quite a host of other viruses)to be priced as low as possible so everybody could afford it worldwide. So now you have a very low cost (comparatively speaking) for B-IV.
Now go to the B-ABSSSI indication for infections and the need to be able to kill superbugs. I have read where leading antibiotic experts say that a price of $10,000 per treatment would be a steal (compared to some other disease and cancer drugs that go up to $1MM / treatment)if it could save patients where nothing now can.
How can you charge $10,000 for the IV for ABSSSI to get the payback necessary for startups to develop such new antibiotics when you are selling the exact same IV for CV and virus treatment patients at a rock bottom price of say $800 / treatment?
Take the same path for COPD, kidney problems, bowel problems, etc, etc. That is why I believe the entire B platform must be handled by a single BP. They would make enough in bulk and have enough patients to generate massive revenues while being able to price B at a reasonable level.
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼